Wall Street Zen Downgrades Precipio (NASDAQ:PRPO) to Hold
by Jessica Moore · The Cerbat GemPrecipio (NASDAQ:PRPO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
View Our Latest Stock Report on Precipio
Precipio Price Performance
Shares of NASDAQ:PRPO opened at $26.04 on Friday. The company’s fifty day moving average price is $27.84 and its 200-day moving average price is $24.87. The firm has a market capitalization of $46.61 million, a price-to-earnings ratio of -55.40 and a beta of 1.38. Precipio has a one year low of $7.31 and a one year high of $33.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.33.
Precipio (NASDAQ:PRPO – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The company had revenue of $6.71 million for the quarter.
Institutional Trading of Precipio
Several hedge funds and other institutional investors have recently bought and sold shares of PRPO. AMH Equity Ltd raised its holdings in Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares during the last quarter. Topline Capital Management LLC bought a new stake in shares of Precipio in the third quarter worth about $1,158,000. Evernest Financial Advisors LLC purchased a new position in Precipio during the 3rd quarter valued at about $374,000. Renaissance Technologies LLC increased its holdings in Precipio by 33.1% during the 1st quarter. Renaissance Technologies LLC now owns 19,300 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 4,800 shares during the period. Finally, Geode Capital Management LLC raised its position in Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares during the last quarter. Institutional investors own 10.45% of the company’s stock.
Precipio Company Profile
Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.
The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.